Skip to main content
. 2022 Aug 29;12(14):6422–6436. doi: 10.7150/thno.77350

Figure 4.

Figure 4

CircRNA-LNP vaccine inhibits the tumor growth and drives potent antigen specific T cell response in MC38 subcutaneous tumor model. (A) Timeline of the experiment to evaluate the anti-tumor efficacy of circRNAOVA-luc-LNP vaccine in MC38 subcutaneous injection model, intramuscular vaccination (10 µg circRNA per mouse). (B) Average tumor growth curve of the mice after different administrations (n = 5). NT, not treated; PBS, PBS-LNP complex; M1Ψ mRNAOVA-luc, M1Ψ mRNAOVA-luc-LNP complex; circRNAOVA-luc, circRNAOVA-luc-LNP. (C) Representative flow dot plots and (D) statistical result of the H-2Kb/SIINFEKL tetramer-positive T cells in PBMCs on day 6 post first immunization. (E) Representative flow dot plots and statistical data of the percentage of (F) IFN-γ and (G) TNF-α positive CD8+ T cells in the spleen at day 28. (H) IFN-γ spot-forming cells and (I) statistical data from restimulated splenocytes determined via Elispot assay at day 28. *p < 0.05, **p < 0.01, ***p < 0.001.